Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Hansen

Showing results (321-330 of 335) with videos related to

Pageof 34
Sort By:
Scandinavian Journal of Rheumatology|August 29, 2013
Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progressionT Ellingsen, I Hansen, J Thorsen, et al.
The Pharmacogenomics Journal|May 6, 2015
Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritisS B Krintel, C Dehlendorff, M L Hetland, et al.
Annals of the Rheumatic Diseases|April 5, 2008
MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA)M L Hetland, B Ejbjerg, K Hørslev-Petersen, et al.
Reproductive Health|May 26, 2016
The Antenatal Corticosteroids Trial (ACT)'s explanations for neonatal mortality - a secondary analysisFernando Althabe, Vanessa Thorsten, Karen Klein, et al.
Annals of the Rheumatic Diseases|May 11, 2013
Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trialT W Jensen, M S Hansen, K Hørslev-Petersen, et al.
Scandinavian Journal of Rheumatology|July 10, 2018
Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trialC H Brahe, M Østergaard, J S Johansen, et al.
Pediatrics|April 27, 2011
Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continuesBarbara J Stoll, Nellie I Hansen, Pablo J Sánchez, et al.
JAMA|January 18, 2022
Mortality, In-Hospital Morbidity, Care Practices, and 2-Year Outcomes for Extremely Preterm Infants in the US, 2013-2018Edward F Bell, Susan R Hintz, Nellie I Hansen, et al.
JAMA|September 9, 2015
Trends in Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates, 1993-2012Barbara J Stoll, Nellie I Hansen, Edward F Bell, et al.
Clinical Rheumatology|December 7, 2016
Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trialL M Ørnbjerg, M Østergaard, T Jensen, et al.
Pageof 34

Showing results (321-330 of 335) with videos related to

Sort By:
Pageof 34
Scandinavian Journal of Rheumatology|August 29, 2013
Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progressionT Ellingsen, I Hansen, J Thorsen, et al.
The Pharmacogenomics Journal|May 6, 2015
Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritisS B Krintel, C Dehlendorff, M L Hetland, et al.
Annals of the Rheumatic Diseases|April 5, 2008
MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA)M L Hetland, B Ejbjerg, K Hørslev-Petersen, et al.
Reproductive Health|May 26, 2016
The Antenatal Corticosteroids Trial (ACT)'s explanations for neonatal mortality - a secondary analysisFernando Althabe, Vanessa Thorsten, Karen Klein, et al.
Annals of the Rheumatic Diseases|May 11, 2013
Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trialT W Jensen, M S Hansen, K Hørslev-Petersen, et al.
Scandinavian Journal of Rheumatology|July 10, 2018
Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trialC H Brahe, M Østergaard, J S Johansen, et al.
Pediatrics|April 27, 2011
Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continuesBarbara J Stoll, Nellie I Hansen, Pablo J Sánchez, et al.
JAMA|January 18, 2022
Mortality, In-Hospital Morbidity, Care Practices, and 2-Year Outcomes for Extremely Preterm Infants in the US, 2013-2018Edward F Bell, Susan R Hintz, Nellie I Hansen, et al.
JAMA|September 9, 2015
Trends in Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates, 1993-2012Barbara J Stoll, Nellie I Hansen, Edward F Bell, et al.
Clinical Rheumatology|December 7, 2016
Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trialL M Ørnbjerg, M Østergaard, T Jensen, et al.
Pageof 34